Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1
GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.
GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.
The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise’s ImSus®…
- Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments
- Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4, 2020
- Virologists and epidemiologists call for continuous testing to contain the pandemic
- The DiagnostikNet-BB works on many levels of the test chain
- IMDB develops new project family for comprehensive COVID-19 diagnostics
ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the…
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces 2015229103 entitled “Antibody molecules to LAG- 3 and uses thereof” by the Australian Patent Office.
Eternygen announces today the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment…
The “Mobile Autonomy for Children in End-stage Heart Failure” (MACH) project wins the 2020 Horizon Impact Award. This project was an international collaboration between RWTH Aachen University, Uniklinik RWTH Aachen, Newcastle upon Tyne Hospitals NHS…
Double interview with Prof. Dr. Christian Drosten, Director of the Institute of Virology at Charité Berlin and speaker at the World Health Summit, and Prof. Dr. Detlev Ganten, President and Founder of the World Health Summit.
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, pioneering computational pathology for pharmaceutical research and diagnostics, has announced today the closing of €5m in seed round funding.…